Skip to main content
|
  1. Home
  2. Clinical Trials
  3. M25-287

Telisotuzumab Adizutecan With Osimertinib as First-Line Treatment in Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Short Title: M25-287


Enrollment Status: Recruiting

NCT #: NCT07005102

Specialty Area: Oncology

Condition Studied: Locally Advanced Unresectable or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Age Groups: Adult; Older Adult

Phase: II/III


Study Information

Summary / Purpose

To find out how safe and effective telisotuzumab adizutecan is when combined with osimertinib compared to osimertinib alone or standard of care in treating EGFR-mutated advanced or metastatic non-small cell lung cancer.

Study Type: Interventional
Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:
  • Adults 18+ years of age
  • Diagnosed with non-squamous Non-Small Cell Lung cancer (NSCLC)
  • Cancer must be EGFR-mutated
  • Cancer must have moved into nearby tissue (locally advanced) and cannot be removed by surgery (unresectable) or must have spread (metastatic)
  • No prior treatment for advanced or metastatic NSCLC

What's Involved

Participation in the study will include:
  • Treatment with osimertinib given orally with or without telisotuzumab adizutecan given intravenously (IV), or standard of care
  • Imaging tests to monitor response to treatment
  • Blood tests to monitor your health and treatment effects
  • Questionnaires

Principal Investigator

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT07005102

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

ER Wait Times

How are wait times calculated?

Our estimated ER wait times reflect the average time from check-in to being seen by a medical professional during triage, where patients are prioritized based on the severity of their condition.

Health & Wellness eNews
Sign Up